ArticleBMC pulmonary medicine2026
Case reports of immune-associated pneumonia with radiological cavity formation.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionCheckpoint inhibitor-associated pneumonitis (CIP) is typically characterized by various radiographic patterns, including organizing pneumonia (OP), nonspecific interstitial pneumonia (NSIP), acute interstitial pneumonia (AIP), usual interstitial pneumonia (UIP), hypersensitivity pneumonitis (HP), and diffuse alveolar damage (DAD). However, cavitary lung lesions on chest CT images have rarely been described in the literature. CASE PRESENTATION: This article reports two lung cancer patients treated with immune checkpoint inhibitors (ICIs) who developed cavitary lung lesions on chest CT. Histopathology of OP with lymphocytic infiltration was supported by multiplex immunofluorescence. After excluding infection and tumour progression, CIP was diagnosed on the basis of the patient’s history of ICI use, clinical presentation, imaging characteristics, laboratory findings, and pathological results. Both patients responded well to glucocorticoids, showing complete or near-complete resolution of cavitary lesions. After steroid discontinuation, the first patient underwent right upper lobectomy followed by adjuvant chemotherapy. After lung cancer recurrence, the patient received combined chemotherapy, immunotherapy, and radiotherapy, with no observed recurrence of CIP during follow-up. The second patient has been receiving traditional chinese medicine treatment since 2025 at another hospital.
conclusionCIP rarely presents with cavitary lung lesions on CT, and careful differentiation of CIP from infectious aetiologies is essential. Empirical management may lead to treatment failure; therefore, imaging and biopsy are crucial for precise patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.